Ocular Therapeutix Inc. (NASDAQ:OCUL)’s share price hit a new 52-week low during trading on Tuesday . The company traded as low as $4.34 and last traded at $4.67, with a volume of 360,747 shares changing hands. The stock had previously closed at $4.42.

OCUL has been the subject of a number of research analyst reports. Morgan Stanley restated an “overweight” rating and set a $16.00 target price (down from $17.00) on shares of Ocular Therapeutix in a report on Tuesday, June 7th. Zacks Investment Research cut Ocular Therapeutix from a “buy” rating to a “hold” rating in a report on Wednesday, May 11th. Cowen and Company restated a “buy” rating on shares of Ocular Therapeutix in a report on Monday, June 6th. Royal Bank Of Canada restated an “outperform” rating and set a $48.00 target price on shares of Ocular Therapeutix in a report on Sunday, April 10th. Finally, BTIG Research restated a “buy” rating and set a $18.00 target price on shares of Ocular Therapeutix in a report on Tuesday. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $27.45.

The stock’s 50 day moving average price is $5.46 and its 200-day moving average price is $8.35. The company’s market cap is $114.91 million.

Ocular Therapeutix (NASDAQ:OCUL) last posted its quarterly earnings data on Tuesday, May 10th. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.43) by $0.01. The company had revenue of $458 million for the quarter. On average, equities research analysts expect that Ocular Therapeutix Inc. will post ($1.86) earnings per share for the current fiscal year.

In related news, CEO Amarpreet Sawhney acquired 10,000 shares of the company’s stock in a transaction that occurred on Thursday, June 9th. The stock was purchased at an average price of $6.70 per share, for a total transaction of $67,000.00. Following the transaction, the chief executive officer now directly owns 573,733 shares of the company’s stock, valued at approximately $3,844,011.10. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Ocular Therapeutix, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.